Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.54 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.53 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.53 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20497268 | 0.85 | SMYD3 (0.52) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL20497236 | 0.85 | KDM5A (0.52) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL20497287 | 0.84 | MAPK1 (0.48) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL29448436 | 0.84 | SMYD3 (0.51) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL17518488 | 0.84 | SMYD3 (0.51) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL22883635 | 0.84 | SMYD3 (0.51) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL20497245 | 0.84 | MAPK1 (0.48) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL17396123 | 0.80 | SMYD3 (0.47) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL20497293 | 0.80 | SMYD3 (0.47) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL17518582 | 0.79 | BTK (0.50) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191489-B1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-01-06 | — | — | EP | disclosed |
| US-10597390-B2 | Indoles for use in influenza virus infection | JANSSEN SCIENCES IRELAND UC (IE) | 2020-03-24 | — | — | US | disclosed |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| WO-2016020526-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN SCIENCES IRELAND UC (IE) | 2016-02-11 | — | — | WO | disclosed |
| WO-2012083117-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597390-B2 | Indoles for use in influenza virus infection | IDO1, IDO2, INMT | SMN1; SMN2 4828/4885NPC1 2751/4885RAB9A 2786/4885 |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | IDO1, IDO2, INMT | SMN1; SMN2 4828/4885NPC1 2751/4885RAB9A 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.